Saturday 17 October 2026
Export SOLV’s income statement to Excel — free account
Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024. In the quarter to June 2026, revenue grew 2.22%, EPS grew 1.92%, free cash flow grew 144.1% and total debt fell 32.4%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years; insiders bought in the last twelve months.
85.81
2.05
−2.33%
Follow SOLV
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 5 |
P/E ratio |
10.26 | 10.26 | 24.02 | 8.87 |
Altman Z-Score |
— | — | 1.47 | 2.22 |
P/S ratio |
1.69 | 1.69 | 1.39 | 1.66 |
Altman Z″-Score (non-manufacturers) |
— | — | 1.05 | 2.34 |
P/FCF ratio |
8.50 | 8.50 | 14.21 | 0.00 |
Beneish M-Score |
— | — | (4.40) | (2.07) |
P/Operating CF |
25.26 | 25.26 | 52.24 | 145.22 |
P/B ratio |
1.18 | 1.18 | 3.87 | 2.73 |
Price to Tangible BV |
6.20 | 6.20 | 0.00 | 0.00 |
EV/Sales |
1.66 | 1.66 | 2.26 | 2.17 |
EV/EBITDA |
6.05 | 6.05 | 11.75 | 6.76 |
EV/Operating CF |
7.11 | 7.11 | 15.77 | 48.92 |
EV/FCF |
8.38 | 8.38 | 23.22 | (1,805.27) |
Quick Ratio |
— | 0.87 | 0.74 | 0.66 |
Current Ratio |
— | 1.46 | 1.20 | 1.23 |
Net Debt/EBITDA |
0.00 | (0.09) | 4.56 | 1.56 |
Debt/Assets |
0.00% | 0.00% | 55.41% | 35.22% |
Debt/Equity |
0.00 | 0.00 | 2.71 | 1.00 |
Asset Turnover |
0.00 | 1.18 | 0.58 | 0.58 |
Operating CF/Net income |
1.25 | 1.42 | 2.47 | 0.24 |
Capex/Depreciation |
(0.43) | (0.52) | (0.68) | (0.78) |
Interest Coverage |
— | — | 2.82 | 6.29 |
| 0.00% | 0.00% | 6.55% | 38.86% | |
| 0.00% | 19.31% | 3.37% | 10.82% | |
ROIC |
0.00% | 9.22% | 6.34% | 14.81% |
Return on Tangible Assets |
0.00% | 59.88% | 22.09% | 75.94% |
Average Days of Receivables |
0.00 | 58.47 | 54.35 | 51.91 |
Research and Development Expense of Revenue |
9.43% | 9.25% | 9.39% | 8.88% |
Selling, General and Administrative Expense of Revenue |
27.49% | 28.05% | 33.70% | 37.00% |
Intangible Assets out of Total Assets |
0.00 | 0.68 | 0.62 | 0.58 |
Share Based Compensation of Revenue |
0.46% | 0.48% | 1.36% | 1.93% |
Graham Net Nets |
0.02 | 0.02 | (0.72) | (0.39) |
Graham Number |
0.00 | 108.84 | 32.51 | 76.34 |
Earnings Yield |
9.74% | 9.74% | 4.16% | 11.27% |
Free Cash Flow Yield |
11.76% | 11.76% | 7.04% | (0.07%) |
Revenue per Share |
47.08 | 47.46 | 47.66 | 47.82 |
Operating CF per Share |
9.72 | 11.09 | 6.84 | 2.12 |
Capex per Share |
(1.45) | (1.68) | (2.19) | (2.18) |
Free Cash Flow per Share |
8.27 | 9.41 | 4.65 | (0.06) |
Cash per Share |
0.00 | 1.12 | 4.40 | 5.04 |
Shareholders Equity per Share |
0.00 | 67.55 | 17.08 | 29.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 67.55 | 17.08 | 29.00 |
Free Cash Flow |
1,428.00 | 1,625.00 | 805.00 | (10.00) |
Working Capital |
— | 791.00 | 546.00 | 723.00 |
Capital Expenditures |
(251.00) | (290.00) | (380.00) | (379.00) |
Net Current Asset Value |
0.00 | 242.00 | (8,249.00) | (5,386.00) |
EV/EBIT |
8.05 | 8.05 | 18.04 | 8.28 |
Capex to Sales |
0.03 | 0.04 | 0.05 | 0.05 |
Price to Operating Income |
8.17 | 8.17 | 11.04 | 6.33 |
| Other line items | ||||
Depreciation/Fixed assets |
0.00 | 0.39 | 0.34 | 0.37 |
Cash ROIC |
0.00% | 13.70% | 6.86% | (0.09%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 6.49 | 6.90 |
Accounts Payable Turnover |
0.00 | 0.00 | 6.69 | 5.94 |
Inventory Turnover |
0.00 | 0.00 | 4.02 | 3.81 |
Average Days of Payables |
0.00 | 49.69 | 61.61 | 64.73 |
Days of Inventory on Hand |
0.00 | 89.27 | 96.21 | 100.44 |
Average Receivables |
— | — | 1,271.00 | 1,206.50 |
Average Payables |
— | — | 547.50 | 652.50 |
Average Inventory |
— | — | 911.00 | 1,015.50 |
Average Assets |
— | 6,971.50 | 14,200.00 | 14,375.50 |
Average Common Equity |
— | — | 7,312.50 | 4,004.50 |
Columns are period end dates